+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Stem Cells Market - Global Forecast 2026-2032- Product Image
Stem Cells Market - Global Forecast 2026-2032- Product Image
Sale

Stem Cells Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6082652
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Stem Cells Market is projected to reach USD 17.40 Billion in 2026. It is expected to continue growing at a CAGR of 11.26%, reaching USD 33.18 Billion by 2032.

Stem cells sit at the center of regenerative medicine, cell therapy, disease modeling, drug discovery, and biomanufacturing. The field spans hematopoietic stem cells used in transplantation, mesenchymal stromal cells studied for immunomodulation and tissue repair, embryonic stem cells, induced pluripotent stem cells, and adult tissue-specific stem cells. Commercial momentum is being shaped by the convergence of clinical demand for durable therapies, better characterization tools, scalable manufacturing, and clearer regulatory expectations from agencies such as the U.S. FDA, EMA, PMDA, Health Canada, and Japan’s MHLW.

The strongest near-term demand is anchored in validated clinical use cases, especially hematopoietic stem cell transplantation and approved cord-blood-derived hematopoietic progenitor cell products. Long-term growth is tied to iPSC-derived cell therapies, organoids, exosome research, stem-cell-enabled drug screening, and advanced cell-based disease models. For decision-makers, the market opportunity is less about a single technology and more about building compliant, reproducible, and evidence-generating platforms that can move from laboratory innovation to regulated clinical and commercial deployment.

Transformative Shifts in the Stem Cells Landscape

The stem cells landscape is moving from exploratory research toward platform-based clinical translation. A decade ago, many programs were limited by inconsistent cell characterization, small-batch production, and uncertain clinical endpoints. Today, single-cell analysis, potency assays, closed-system processing, cryopreservation improvements, digital batch records, and standardized donor-screening practices are helping developers reduce variability and improve comparability across clinical phases.

Transformative shifts are also occurring in disease focus and operating models. Oncology, hematology, musculoskeletal disorders, autoimmune diseases, ophthalmology, diabetes, and neurodegenerative conditions remain high-priority areas, while drug developers increasingly use stem-cell-derived models to de-risk pipelines before human trials. Strategic partnerships among biopharma developers, academic medical centers, contract development and manufacturing organizations, transplant networks, and cord blood banks are becoming central to scaling therapies while meeting good manufacturing practice, pharmacovigilance, and long-term follow-up requirements.

Cumulative Impact of Artificial Intelligence on Stem Cells

Artificial intelligence is becoming a practical accelerator across stem cell research and commercialization. In discovery, machine learning supports single-cell transcriptomics interpretation, cell-state classification, differentiation protocol optimization, image-based phenotyping, and target identification. In manufacturing, computer vision and predictive analytics can monitor morphology, culture conditions, contamination risk, media performance, and batch consistency, reducing reliance on subjective manual assessment.

The cumulative impact of AI is most visible where large biological datasets intersect with repeatable process controls. AI-enabled quality analytics can help predict potency, flag deviations earlier, and shorten development cycles when supported by validated datasets and regulatory-grade documentation. However, industry leaders must address data provenance, model explainability, bias in training datasets, cybersecurity, and compliance with evolving rules for software, laboratory automation, and clinical decision support. AI will not replace biological validation, but it can materially improve the speed, traceability, and reproducibility of stem cell innovation.

Key Regional Insights Across the Stem Cells Landscape

North America remains a leading stem cells hub because of deep translational research infrastructure, established clinical trial networks, active transplant registries, sophisticated bioprocessing capacity, and regulatory oversight by the FDA and Health Canada. The United States leads in clinical research density, manufacturing capability, and regulated cell therapy commercialization, while Canada contributes strength in regenerative medicine networks, public-private research programs, clinical trial coordination, and bioprocessing expertise.

Europe benefits from advanced therapy medicinal product regulation, strong academic hospitals, national health systems, and coordinated research funding across the European Union, with Germany, France, Spain, Italy, and the United Kingdom supporting robust clinical and manufacturing ecosystems. Asia-Pacific is a fast-moving innovation arena, led by Japan’s regenerative medicine framework and iPSC leadership, China’s expanding clinical trial base and manufacturing scale, South Korea’s advanced cell therapy ecosystem, Australia’s high-quality trial infrastructure, and India’s growing biomanufacturing and clinical research base.

Latin America is advancing through Brazil and Mexico, where clinical research capacity, public health demand, university hospitals, and private hospital networks support selective growth in regulated stem cell applications. The Middle East, particularly GCC countries, is investing in medical tourism, specialty hospitals, biotechnology diversification, and internationally aligned healthcare infrastructure. Africa remains earlier-stage but strategically important, with opportunities in cord blood banking, academic collaborations, transplant capacity-building, and ethical frameworks for regulated regenerative medicine.

Key Group Insights for Stem Cells Growth

ASEAN is emerging as a cost-competitive clinical research and medical services corridor, with Singapore providing regulatory sophistication, biomedical infrastructure, and translational research depth while Thailand, Malaysia, Indonesia, Vietnam, and the Philippines develop healthcare capacity and regenerative medicine interest. The GCC is using national diversification strategies to expand biotechnology, specialty care, clinical research, and medical tourism, creating demand for compliant stem cell services and partnerships with established global institutions.

The European Union remains pivotal through harmonized advanced therapy regulation, Horizon Europe research funding, shared scientific standards, and cross-border clinical research networks. BRICS countries provide scale, patient diversity, manufacturing potential, and rising public investment in biotechnology, although regulatory maturity and reimbursement pathways vary considerably across members. G7 markets continue to set benchmarks for evidence generation, reimbursement scrutiny, intellectual property protection, GMP manufacturing, and post-approval surveillance. NATO members are not a healthcare market bloc, but their overlapping strengths in biomedical research, supply-chain resilience, biosecurity, and defense-linked health preparedness influence strategic investment in advanced therapies and regenerative medicine infrastructure.

Key Country Insights in Stem Cells

The United States is the most commercially mature stem cells environment, driven by FDA-regulated cell therapies, NIH-funded research, leading academic medical centers, transplant expertise, and a large biopharma ecosystem. Canada has strong regenerative medicine coordination, clinical trial expertise, and supportive research networks, while Mexico is building demand through private healthcare, specialist hospitals, and proximity to North American clinical and manufacturing networks. Brazil leads Latin America with major hospitals, universities, cell therapy research programs, and a large domestic patient base.

In Europe, the United Kingdom combines cell and gene therapy infrastructure with strong translational science and clinical trial capabilities, Germany leads in biomanufacturing and hospital-based research, France supports national innovation programs and academic medicine, Italy and Spain contribute active transplant and regenerative medicine networks, and Russia maintains scientific capacity despite market-access and geopolitical constraints. In Asia-Pacific, China is scaling clinical research and manufacturing, India is expanding biotechnology capacity and clinical trial infrastructure, Japan benefits from a defined regenerative medicine pathway and iPSC leadership, Australia offers high-quality early-phase trials and strong regulatory standards, and South Korea has a developed cell therapy industry, advanced hospital system, and supportive innovation policies.

Actionable Recommendations for Stem Cells Leaders

Industry leaders should prioritize evidence quality, manufacturing reproducibility, and regulatory alignment from the earliest stages of development. Programs should define critical quality attributes, validated potency assays, cell identity markers, sterility controls, donor eligibility procedures, chain-of-identity controls, chain-of-custody documentation, and long-term follow-up plans before scaling clinical activity. Early engagement with regulators can reduce delays and clarify expectations for comparability, release testing, safety monitoring, and post-treatment surveillance.

Organizations should invest in closed and automated manufacturing, digital quality systems, cryogenic logistics, validated analytics, and AI-supported process monitoring. Partnerships with academic centers, CDMOs, cord blood banks, transplant groups, and hospital networks can accelerate recruitment and operational execution. Commercial planning should include payer evidence, health economics, real-world data capture, patient access design, and ethical communication that avoids overstating unapproved stem cell interventions. The most defensible strategies will combine scientific rigor with scalable operations and transparent patient safety practices.

Research Methodology

This executive summary is built on triangulated secondary research and life sciences market intelligence practices. Inputs include regulatory databases and guidance from the FDA, EMA, PMDA, Health Canada, WHO resources, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform, national trial registries, and public information from transplant and regenerative medicine organizations such as CIBMTR, EBMT, ISSCR, and recognized cord blood and cell therapy bodies.

The assessment also reviews peer-reviewed literature, patent activity, public disclosures, investor presentations, reimbursement and policy updates, hospital and academic program information, and manufacturing capacity signals. Insights are validated through cross-comparison of regulatory status, clinical evidence, regional infrastructure, and commercialization readiness. No section relies on promotional claims from unverified clinics, and conclusions emphasize regulated, evidence-backed stem cell applications.

Conclusion

The stem cells landscape is entering a more disciplined phase in which credible growth depends on clinical evidence, manufacturing control, regulatory compliance, and responsible commercialization. Established transplantation uses provide a validated foundation, while iPSC platforms, organoids, engineered cells, exosome research, and AI-enabled analytics expand the long-term opportunity across therapy development and drug discovery.

Regional competition is intensifying as North America and Europe deepen clinical translation, Asia-Pacific scales innovation, and emerging regions invest in capacity. The winners will be organizations that convert biological complexity into repeatable products, generate durable safety and efficacy data, and build trusted ecosystems with regulators, clinicians, manufacturers, and patients. Stem cells remain one of the most important frontiers in regenerative medicine, but sustainable leadership will come from evidence, reproducibility, and patient safety rather than hype.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Stem Cells Market, by Cell Type
7.1. Introduction
7.2. Adult Stem Cells
7.3. Human Embryonic Stem Cells
7.4. Induced Pluripotent Stem Cells
8. Stem Cells Market, by Cell Source
8.1. Introduction
8.2. Allogeneic
8.3. Autologous
9. Stem Cells Market, by Technology
9.1. Introduction
9.2. Bioprinting
9.3. Cell Culture
9.4. Gene Editing
9.4.1. CRISPR
9.4.2. Transcription Activator-Like Effector Nuclease
10. Stem Cells Market, by Cell Source
10.1. Introduction
10.2. Adipose Tissue
10.3. Amniotic Cells
10.4. Bone Marrow
10.5. Peripheral Blood
10.6. Umbilical Cord
11. Stem Cells Market, by Application
11.1. Introduction
11.2. Cell Banking
11.3. Drug Discovery & Testing
11.3.1. Pharmaceutical Screening
11.3.2. Toxicity Testing
11.4. Regenerative Medicine
11.4.1. Cardiovascular
11.4.2. Neurology
11.4.3. Orthopaedics
11.5. Research & Development
12. Stem Cells Market, by End User
12.1. Introduction
12.2. Biopharmaceutical Companies
12.3. Contract Research Organizations
12.4. Hospitals & Clinics
12.5. Research Institutes
13. Stem Cells Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Stem Cells Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Stem Cells Market, by Country
15.1. United States
15.2. Germany
15.3. China
15.4. United Kingdom
15.5. India
15.6. Japan
15.7. Russia
15.8. Brazil
15.9. Canada
15.10. Italy
15.11. Mexico
15.12. France
15.13. Spain
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Advanced Cell Technology, Inc.
17.2. AlloSource, Inc.
17.3. Anterogen Co., Ltd.
17.4. Athersys Inc.
17.5. Becton, Dickinson and Company
17.6. Bioheart Inc.
17.7. Biorestorative Therapies Inc.
17.8. BrainStorm Cell Therapeutics Inc.
17.9. Bristol-Myers Squibb Company
17.10. Cellartis AB
17.11. Cellular Engineering Technologies Inc.
17.12. Charles River Laboratories International, Inc.
17.13. Danaher Corporation
17.14. Gamida Cell Ltd
17.15. GE HealthCare by General Electric Company
17.16. GenScript Biotech Corporation
17.17. Gilead Sciences, Inc.
17.18. HOLOSTEM S.r.l. by Chiesi Farmaceutici S.p.A
17.19. JCR Pharmaceuticals Co., Ltd.
17.20. Lonza Group AG
17.21. Merck KGaA
17.22. Novartis AG
17.23. Pluristyx, Inc.
17.24. Sartorius AG
17.25. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL STEM CELLS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL STEM CELLS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL STEM CELLS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL STEM CELLS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL STEM CELLS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL STEM CELLS MARKET SIZE, BY CELL TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL STEM CELLS MARKET SIZE, BY CELL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL STEM CELLS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL STEM CELLS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL STEM CELLS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL STEM CELLS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL STEM CELLS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL STEM CELLS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL STEM CELLS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL STEM CELLS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL STEM CELLS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ADULT STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ADULT STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ADULT STEM CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL ALLOGENEIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL ALLOGENEIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ALLOGENEIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL AUTOLOGOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL AUTOLOGOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL AUTOLOGOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL BIOPRINTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL BIOPRINTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL BIOPRINTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CELL CULTURE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL CELL CULTURE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL CELL CULTURE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL GENE EDITING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL GENE EDITING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL GENE EDITING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL CRISPR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CRISPR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CRISPR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ADIPOSE TISSUE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ADIPOSE TISSUE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ADIPOSE TISSUE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL AMNIOTIC CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL AMNIOTIC CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL AMNIOTIC CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL BONE MARROW MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL BONE MARROW MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL BONE MARROW MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL PERIPHERAL BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PERIPHERAL BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL PERIPHERAL BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL UMBILICAL CORD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL UMBILICAL CORD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL UMBILICAL CORD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CELL BANKING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CELL BANKING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CELL BANKING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL DRUG DISCOVERY & TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL DRUG DISCOVERY & TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL DRUG DISCOVERY & TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PHARMACEUTICAL SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PHARMACEUTICAL SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PHARMACEUTICAL SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL TOXICITY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL TOXICITY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL TOXICITY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ORTHOPAEDICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ORTHOPAEDICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ORTHOPAEDICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 124. EUROPE STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. EUROPE STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 126. EUROPE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 127. EUROPE STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 128. EUROPE STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 129. EUROPE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 130. EUROPE STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 131. EUROPE STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 132. EUROPE STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 133. EUROPE STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 143. MIDDLE EAST STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. AFRICA STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. AFRICA STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 146. AFRICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 147. AFRICA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 148. AFRICA STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 149. AFRICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 150. AFRICA STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 151. AFRICA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 152. AFRICA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 153. AFRICA STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. ASEAN STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 156. ASEAN STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 157. ASEAN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 158. ASEAN STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 159. ASEAN STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 160. ASEAN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 161. ASEAN STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 162. ASEAN STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 163. ASEAN STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 164. ASEAN STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 165. GCC STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. GCC STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 167. GCC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 168. GCC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 169. GCC STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 170. GCC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 171. GCC STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 172. GCC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 173. GCC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 174. GCC STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 185. BRICS STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 186. BRICS STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 187. BRICS STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 188. BRICS STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 189. BRICS STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 190. BRICS STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 191. BRICS STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 192. BRICS STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 193. BRICS STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 194. BRICS STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 195. G7 STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 196. G7 STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 197. G7 STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 198. G7 STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 199. G7 STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 200. G7 STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 201. G7 STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 202. G7 STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 203. G7 STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 204. G7 STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 205. NATO STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 206. NATO STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 207. NATO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 208. NATO STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 209. NATO STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 210. NATO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 211. NATO STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 212. NATO STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 213. NATO STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 214. NATO STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 216. UNITED STATES STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 217. UNITED STATES STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 218. UNITED STATES STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 219. UNITED STATES STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 220. UNITED STATES STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 221. UNITED STATES STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 222. UNITED STATES STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 223. UNITED STATES STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 224. UNITED STATES STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 225. UNITED STATES STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 226. GERMANY STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 227. GERMANY STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 228. GERMANY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 229. GERMANY STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 230. GERMANY STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 231. GERMANY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 232. GERMANY STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 233. GERMANY STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 234. GERMANY STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 235. GERMANY STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. CHINA STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. CHINA STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 238. CHINA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 239. CHINA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 240. CHINA STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 241. CHINA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 242. CHINA STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 243. CHINA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 244. CHINA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 245. CHINA STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 250. UNITED KINGDOM STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 251. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 252. UNITED KINGDOM STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 253. UNITED KINGDOM STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 254. UNITED KINGDOM STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 255. UNITED KINGDOM STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 256. INDIA STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 257. INDIA STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 258. INDIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 259. INDIA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 260. INDIA STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 261. INDIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 262. INDIA STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 263. INDIA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 264. INDIA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 265. INDIA STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 266. JAPAN STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 267. JAPAN STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 268. JAPAN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 269. JAPAN STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 270. JAPAN STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 271. JAPAN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 272. JAPAN STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 273. JAPAN STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 274. JAPAN STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 275. JAPAN STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 276. RUSSIA STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 277. RUSSIA STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 278. RUSSIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 279. RUSSIA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 280. RUSSIA STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 281. RUSSIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 282. RUSSIA STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 283. RUSSIA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 284. RUSSIA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 285. RUSSIA STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 286. BRAZIL STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 287. BRAZIL STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 288. BRAZIL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 289. BRAZIL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 290. BRAZIL STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 291. BRAZIL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 292. BRAZIL STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 293. BRAZIL STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 294. BRAZIL STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 295. BRAZIL STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 296. CANADA STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 297. CANADA STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 298. CANADA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 299. CANADA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 300. CANADA STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 301. CANADA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 302. CANADA STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 303. CANADA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 304. CANADA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 305. CANADA STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 306. ITALY STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 307. ITALY STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 308. ITALY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 309. ITALY STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 310. ITALY STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 311. ITALY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 312. ITALY STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 313. ITALY STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 314. ITALY STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 315. ITALY STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 316. MEXICO STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 317. MEXICO STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 318. MEXICO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 319. MEXICO STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 320. MEXICO STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 321. MEXICO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 322. MEXICO STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 323. MEXICO STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 324. MEXICO STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 325. MEXICO STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 326. FRANCE STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 327. FRANCE STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 328. FRANCE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 329. FRANCE STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 330. FRANCE STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 331. FRANCE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 332. FRANCE STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 333. FRANCE STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 334. FRANCE STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 335. FRANCE STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 336. SPAIN STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 337. SPAIN STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 338. SPAIN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 339. SPAIN STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 340. SPAIN STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 341. SPAIN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 342. SPAIN STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 343. SPAIN STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 344. SPAIN STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 345. SPAIN STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 346. AUSTRALIA STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 347. AUSTRALIA STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 348. AUSTRALIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 349. AUSTRALIA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 350. AUSTRALIA STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 351. AUSTRALIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 352. AUSTRALIA STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 353. AUSTRALIA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 354. AUSTRALIA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 355. AUSTRALIA STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 356. SOUTH KOREA STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 357. SOUTH KOREA STEM CELLS MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 358. SOUTH KOREA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 359. SOUTH KOREA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 360. SOUTH KOREA STEM CELLS MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 361. SOUTH KOREA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 362. SOUTH KOREA STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 363. SOUTH KOREA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2017-2032 (USD MILLION)
TABLE 364. SOUTH KOREA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 365. SOUTH KOREA STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 366. GLOBAL STEM CELLS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 367. GLOBAL STEM CELLS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Advanced Cell Technology, Inc.
  • AlloSource, Inc.
  • Anterogen Co., Ltd.
  • Athersys Inc.
  • Becton, Dickinson and Company
  • Bioheart Inc.
  • Biorestorative Therapies Inc.
  • BrainStorm Cell Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • Cellartis AB
  • Cellular Engineering Technologies Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Gamida Cell Ltd
  • GE HealthCare by General Electric Company
  • GenScript Biotech Corporation
  • Gilead Sciences, Inc.
  • HOLOSTEM S.r.l. by Chiesi Farmaceutici S.p.A
  • JCR Pharmaceuticals Co., Ltd.
  • Lonza Group AG
  • Merck KGaA
  • Novartis AG
  • Pluristyx, Inc.
  • Sartorius AG
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 17.4 Billion
Forecasted Market Value ( USD ) by 2032 $ 33.18 Billion
Compound Annual Growth Rate11.2%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Stem Cell Assays Market - Global Forecast 2026-2032 - Product Image

Stem Cell Assays Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Human Embryonic Stem Cells Market - Global Forecast 2026-2032 - Product Image

Human Embryonic Stem Cells Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Stem Cell Services - Global Strategic Business Report - Product Image

Stem Cell Services - Global Strategic Business Report

  • Report
  • 293 Pages
  • Global
From
Stem Cell Assays - Global Strategic Business Report - Product Image

Stem Cell Assays - Global Strategic Business Report

  • Report
  • 246 Pages
  • Global
From
Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2025 - Product Image

Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2025

  • Report
  • 327 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.